OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
ONCOMED PHARMA (NASDAQ: OMED) Delayed: 0.89 --0 (-0%)
Previous Close $0.89    52 Week High $23.98 
Open $16.48    52 Week Low $8.07 
Day High $0.89    P/E N/A 
Day Low $0.89    EPS $-1.00 
Volume 668